Keeping COVID-19 at Bay: Existing and Induced Antibody Immunity to SARS-CoV-2

WEBINAR

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus causing Coronavirus disease 2019 (COVID-19). There is an urgent need to understand the humoral immune responses to SARS-CoV-2 and how they contribute to disease severity and vaccine-induced immunity. Humoral immune responses targeting SARS-CoV-2 viral antigens have been characterized by high-resolution mapping of the antibody responses in adults naturally infected with SARS-CoV-2, children and adults with no history of SARS-CoV-2 infection, and adults immunized with a two-dose COVID-19 messenger RNA (mRNA) vaccine. Most infected and vaccinated adults developed robust antibody responses (in order of prevalence: IgG>IgM>IgA) targeting spike (S) and nucleocapsid (N) proteins of the virus using MILLIPLEX^® multiplexed bead-based binding assays. Individuals who had prior infection showed significantly higher antibody levels to SARS-CoV-2 after a single vaccine dose. While uninfected infants did not have high levels of SARS-CoV-2 cross-reactive antibodies, many children and adults had cross-reactive antibodies that recognize multiple viral antigens. These findings provide insights into SARS-CoV-2 antibody responses after infection, vaccination, and in unexposed populations of children and adults, which can facilitate future vaccine designs.

Our expert speaker, Todd Bradley, director of Immunogenomics at Children’s Mercy Research Institute in Kansas City, Missouri, will:

• Provide an overview of serology tests, what they detect, and how this information can be used
  
• Discuss the difference between existing and induced antibody immunity to SARS-CoV-2 and why antibody response rates differ among patients
  
• Highlight differences in immune responses to vaccines in individuals with a history of prior COVID-19 infection.

For Research Use Only. Not For Use In Diagnostic Procedures.